Navigation Links
Bernstein Liebhard LLP Launches New GranuFlo Lawsuit Website for Individuals Allegedly Injured by Recalled Dialysis Medications

New York, New York (PRWEB) December 08, 2013

The attorneys at Bernstein Liebhard LLP have launched a new website for individuals seeking to file NaturaLyte and GranuFlo lawsuit ( claims. Vital to anyone who may have suffered a stroke, heart attack, sudden cardiac death or another cardiovascular injury allegedly stemming from either of these dialysis medications, information about last year’s GranuFlo recall will be included on the Firm’s new website.

Individuals who are eligible to file a lawsuit against Fresenius Medical Care, the manufacturer of these acid concentrates, may have experienced heart problems within 72 hours of a dialysis treatment that used GranuFlo or NaturaLyte. According to court documents filed in November, almost 400 cases alleging injuries caused by these medications are now pending in a federal litigation underway in the U.S. District Court, District of Massachusetts. (In re Fresenius GranuFlo/Naturalyte Dialysate Litigation, MDL No. 2428)

“With this new website, individuals who may have been injured as a result of GranuFlo or NaturaLyte will be connected with the resources they need to file a claim against Fresenius,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective medical devices and drugs including GranuFlo and NaturaLyte. The Firm is currently offering free and confidential case evaluations to anyone who may have sustained the life-threatening heart problems associated with either of these medications.

GranuFlo Lawsuits
A recent update from the U.S. Judicial Panel on Multidistrict Litigation (JPML) indicates that 393 NaturaLyte and GranuFlo lawsuits were pending in the federal Massachusetts proceeding as of November 18th, 2013. Cases filed in this litigation, which held its most recent status conference on November 1, 2013, were brought on behalf of individuals who received either of the acid concentrates during dialysis treatments and who are alleged to have suffered a stroke, heart attack, sudden cardiac death, or another heart-related injury.

The U.S. Food and Drug Administration (FDA) issued a Class I recall for GranuFlo and NaturaLyte in June 2012 after the federal agency found that the acid concentrates may put a patient at risk for serious injury and death. This announcement followed an Urgent Product Notification from Fresenius in March 2012 that alerted the general public of GranuFlo and NaturaLyte’s association with sudden cardiac death, heart attacks, cardiopulmonary arrest, strokes and other injuries.

According to a New York Times report published shortly after the GranuFlo recall, the FDA’s involvement with the Fresenius medications did not end there. After becoming aware of an internal memo sent in November 2011 to physicians operating in the company’s own dialysis clinics, the federal agency began to investigate whether the dialysis drug supplier violated federal regulations in its handling of the recall. According to the memo, more than 900 deaths had occurred in patients who underwent dialysis treatments aided by GranuFlo and NaturaLyte. Fresenius did not alert doctors in facilities outside its network of these fatalities at the time. *

Dialysis lawsuits filed in U.S. federal and state courts now allege that the manufacturer failed to adequately warn doctors and patients about its products’ risk for these side effects, which may be caused by the acid concentrates’ potential to cause elevated levels of bicarbonate in the bloodstream. In turn, this may result in a condition referred to as metabolic alkalosis.

In addition to claims pending in the federal proceeding, court documents show several GranuFlo and NaturaLyte lawsuits pending in Massachusetts’ Middlesex County Superior Court. (In re: Consolidated Fresenius Cases, No. MICV2013-03400-O)

Dialysis patients who may have suffered cardiovascular side effects within 72 hours of receiving GranuFlo or NaturaLyte may be eligible to file a lawsuit against Fresenius Medical Care. Learn More about the GranuFlo recall by visiting Bernstein Liebhard LLP’s new website, or by speaking with one of the Firm’s lawyers directly. To arrange for a free case review, please call 800-511-5092.

*; New York Times, June 14, 2012

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past 11 consecutive years.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016

ATTORNEY ADVERTISING. © 2013 Bernstein Liebhard LLP. The law firm responsible for this
advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Transvaginal Mesh Lawsuit News: Bernstein Liebhard LLP Notes New Plaintiff Filing in Federal Ethicon Vaginal Mesh Litigation
2. DePuy ASR Lawsuit News: Bernstein Liebhard LLP Notes Issuance of New Order in Federal DePuy ASR Hip Recall Litigation
3. Ethicon Transvaginal Mesh Lawsuits Mount, as Bernstein Liebhard LLP Notes More than 16,000 Filings in Federal, State Litigations
4. DePuy Pinnacle Hip Lawsuit News: Bernstein Liebhard LLP Notes Order Delaying Consideration of Remand Motions in Federal Pinnacle Hip Litigation
5. As Pradaxa Lawsuits Move Forward, Bernstein Liebhard LLP Notes Manufacturer is Working on Possible Antidote for Internal Bleeding Caused by the Blood-Thinner
6. DePuy Pinnacle Lawsuit Claims Mount, as Bernstein Liebhard LLP Notes Nearly 6,000 Filings in Federal Pinnacle Hip Litigation
7. Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Johnson & Johnson Bid to Keep Clinical Studies Under Seal
8. Stryker Hip Lawsuit News: Bernstein Liebhard LLP Notes Scheduling of December Case Management Conference in New Jersey Stryker Hip Recall Litigation
9. Transvaginal Mesh Lawsuits Progress, As Bernstein Liebhard LLP Notes Scheduling of Motions Hearing in Federal Vaginal Mesh Litigations
10. Transvaginal Mesh Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Conference in New Jersey Vaginal Mesh Litigations
11. Federal GranuFlo Lawsuits Progress, as Bernstein Liebhard LLP Notes Issuance of New Case Management Order in GranuFo Recall Litigation
Post Your Comments:
(Date:11/25/2015)... ... November 25, 2015 , ... “While riding the bus, I ... Bronx, N.Y. “I thought there had to be a convenient and comfortable way to ... The PROTECTOR enables disabled individuals to safely travel during cold or inclement weather. In ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... (PHA) announces the nation’s Periwinkle Pioneers, individuals and groups responsible for advancing care ... disease. The Periwinkle Pioneers, nominated by the public, will receive special recognition throughout ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... philanthropic seniors, is resulting in a way for homeless people to have a ... have launched a new initiative whereby they are repurposing plastic bags into sleeping ...
(Date:11/25/2015)... ... November 25, 2015 , ... Since its launch in 2012, ... adult stem cell therapies to patients with chronic degenerative medical conditions. Now, the ... Registered Trademark (RTM). , Organizations are required to hold a registered trademark in ...
(Date:11/24/2015)... ... November 25, 2015 , ... Genesis Chiropractic Software ... software creates an agreement between the practice owner and the patient that automatically ... notification, and projections. Click here to learn more. , ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... FRANCISCO , Nov. 24, 2015  Thanks to ... Dignity Health St. Mary,s Medical Center,s Sister Diane Grassilli ... breast imaging capabilities in San Francisco ... an anonymous friend, stepped forward with a gift of ... for Breast Digital Mammography with Tomosynthesis and Whole Breast ...
(Date:11/24/2015)... Colo. , Nov. 24, 2015  Array ... that its Chief Executive Officer, Ron Squarer ... Healthcare Conference in New York.  The public is ... webcast on the Array BioPharma website.Event:Piper Jaffray Annual ... , Wednesday, December 2, 2015Time:1:30 p.m. Eastern Time ...
(Date:11/24/2015)... HOUSTON, TX and VANCOUVER, Nov. 24, 2015 /PRNewswire/ ... EPI; NASDAQ: EPIX ) announced today that the ... clinical study of EPI-506 as a treatment for metastatic ... States and Canada.  --> ... --> In the Phase 1/2 clinical trial, ...
Breaking Medicine Technology: